March 21st, 2017

Rich Pharmaceuticals To Launch CannCodex, marking its entry into Medicinal Cannabis Industry
View Release

February 28th, 2017

Rich Pharmaceuticals Attracts New Financing Package with GHS Investments, LLC
View Release

September 27th, 2016

Rich Pharmaceuticals, Inc. Announces Quarterly Milestones
View Release

June 21st, 2016

Rich Pharmaceuticals Retains Theradex Systems To Help Advance Its Hodgkin’s Lymphoma Indication
View Release

April 4th, 2016

Rich Pharmaceuticals Retains Contract Research Organization, CMIC, to Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in Thailand
View Release

March 30th, 2016

Rich Pharmaceuticals Further Extends CRO Agreement with Theradex Systems To Manage Upcoming Phase 1/2 Clinical Trial for its Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) Drug in the United States
View Release

February 16th, 2016

Rich Pharmaceuticals, Inc. Highlights Goals and Objectives for 2016
View Release

February 10th, 2016

Rich Pharmaceuticals, Inc. Announces Reverse Split
View Release

December 28th, 2015

Rich Pharmaceuticals, Inc. Receives FDA Approval for a Phase 1/2 Study in AML & MDS
View Release

November 23rd, 2015

Rich Pharmaceuticals Announces Additional Submission To The U.S. Food and Drug Administration (FDA)
View Release

October 7th, 2015

Rich Pharmaceuticals Retains Theradex Systems To Finalize Investigational New Drug Application And Initiate Next Phases Of Clinical Trials
View Release

August 13th, 2015

Rich Pharmaceuticals, Inc. Appoints Richard Salvador, Ph.D., Research & Development Expert, To Board of Directors
View Release

March 18th, 2015

Rich Pharmaceuticals, Inc. Names Chittima Sirijerachai, MD as Principal Investigator for Upcoming AML Clinical Trials
View Release

February 6th, 2015

Rich Pharmaceuticals Announces Completion of the Manufacture of RP-323 Study Drug in Connection with Obtaining FDA’s Final Approval of The Investigational New Drug (IND) Application For The Treatment of Acute Myelocytic Leukemia
View Release

October 23rd, 2014

Rich Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application to FDA for the Treatment of Acute Myelocytic Leukemia and Myelodysplastic Syndrome
View Release

October 13th, 2014

Rich Pharmaceuticals Announces Assignment Agreement Acquiring Complete Ownership, Development and Commercialization Rights for Indication, Patents and Intellectual Property Related to the Treatment of Hodgkin’s Lymphoma
View Release

October 9th, 2014

Rich Pharmaceuticals Announces Up to $4.5 Million Finance Deal to Fund Phase 2 Clinical Trials in Acute Myelocytic Leukemia
View Release

July 23rd, 2014

Rich Pharmaceuticals Hires Contract Research Organization to File IND and Identify Clinical Trial Site(s) for Lead Compound
View Release

May 6th, 2014

Rich Pharmaceuticals Appoints Dr. Chieanchuang Kalayanamitr to Medical Advisory Board
View Release

April 17th, 2014

Rich Pharmaceuticals Appoints Professor Richard L. Chang to Medical Advisory Board
View Release

Stock Price